• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nuclear Medicine and Biology >Intratumoral injection with [Re-188]rhenium sulfide suspension for treatment of transplanted human liver carcinoma in nude mice
【24h】

Intratumoral injection with [Re-188]rhenium sulfide suspension for treatment of transplanted human liver carcinoma in nude mice

机译：瘤内注射[Re-188]硫化hen悬浮液治疗裸鼠移植人肝癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Direct intratumoral injection of nonremovable radioactive material has been widely studied because it could deliver high doses of radiation to target sites and minimize radiation leakage to non-target organs or tissues. Thirty nude mice bearing SMMC 7721 human liver carcinoma were used for the biodistribution study after intratumoral injection of [Re-188]rhenium sulfide suspension or sodium [Re-188]perrhenate solution. Another 30 tumor-bearing mice were divided into six groups, four groups of which were treated with a 0.1 ml [Re-188]rhenium sulfide suspension at doses of 3.7, 7.4, 18.5, 29.6 MBq by a single intratumoral injection. For control studies, to study the tumor inhibiting ratio, the remaining two groups were injected with nonradioactive rhenium sulfide suspension and Hanks' balanced salt solution, respectively. The injections were repeated 6 days later, The retention percentages of radioactivity (%ID) in tumors injected with [Re-188]rhenium sulfide suspension were 90.96 + 6.63%, 86.09 +/- 22.58% and 87.62 +/- 13.97% at 1, 24 and 48 h, respectively. Tumor inhibition ratios are as high as 89% when the outer space of tumor (0.5-0.6 cm from center) received about 507.6 Gy doses. Intratumoral injection of [Re-188]rhenium sulfide suspension results in high tumor retention indicating this approach has strong potential for the treatment of hepatic carcinoma, NUCL MED BIOL 27;4:347-352, 2000. (C) 2000 Elsevier Science Inc. All rights reserved. [References: 12]
机译：肝细胞癌（HCC）是中国最常见的恶性肿瘤之一。肿瘤内直接注射不可移动的放射性物质已经被广泛研究，因为它可以将高剂量的辐射传递到目标部位，并使辐射向非目标器官或组织的泄漏最小化。在瘤内注射[Re-188]硫化hen悬浮液或[Re-188]高hen酸钠溶液后，将30只带有SMMC 7721人肝癌的裸鼠用于生物分布研究。将另外30只荷瘤小鼠分成六组，通过单次肿瘤内注射用0.1ml [Re-188]硫化r悬浮液以3.7、7.4、18.5、29.6MBq的剂量治疗其中的四组。为了进行对照研究，为研究肿瘤抑制率，其余两组分别注射了非放射性硫化rh悬浮液和汉克斯平衡盐溶液。 6天后重复注射。在[Re-188]硫化hen悬浮液注射后的肿瘤中，放射性保留率（％ID）分别为90.96 + 6.63％，86.09 +/- 22.58％和87.62 +/- 13.97％ ，分别为24小时和48小时。当肿瘤的外部空间（距中心0.5-0.6厘米）接受约507.6 Gy剂量时，肿瘤抑制率高达89％。瘤内注射[Re-188]硫化hen悬浮液会导致很高的肿瘤保留，这表明该方法具有治疗肝癌的强大潜力，NUCL MED BIOL 27; 4：347-352，2000。（C）2000 Elsevier Science Inc.版权所有。 [参考：12]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号